Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.
antipsychotic agents
pharmacogenetics
schizophrenia
Journal
Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
21
02
2020
revised:
16
04
2020
accepted:
01
05
2020
pubmed:
29
5
2020
medline:
2
9
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
Antipsychotic drugs are the preferred choice for schizophrenia treatment; however, response is highly variable. In the context of the search for predictors of antipsychotic treatment effectiveness, the evaluation of response within 2 weeks has been indicated to predict long-term outcome. Moreover, a focus on symptomatological domains could be helpful to better characterize antipsychotic response, identifying more specific predictors. Pharmacogenetic studies have indicated a role for rs6313 in the serotonin receptor gene HTR2A in affecting response to antipsychotics, with heterogeneous results. With the aim to test for the first time the application of a dimensional approach for the evaluation of early response, we carried out a genetic association study between rs6313 and antipsychotic response in two groups of schizophrenia patients in monotherapy with risperidone (n = 121) and olanzapine (n = 100). Patients were evaluated at the baseline and after 1 and 2 weeks of treatment. When comparing early responders versus early nonresponders, no association was detected for the two drugs separately, whereas by taking into consideration the two drugs together it was observed that carriers of the T allele had a higher response probability compared to noncarriers. Considering 2-week improvements, changes in PANSS total scores, subscores and in PANSS Emsley's symptomatological dimensions were associated with rs6313 for both risperidone and olanzapine. Moreover, the repeated measures analysis indicated an association of rs6313 with the disorganized thought dimension for risperidone, and with the depressive and anxiety dimensions for olanzapine. These data add support to the hypothesis that the HTR2A gene is involved in antipsychotic treatment outcome.
Substances chimiques
Antipsychotic Agents
0
HTR2A protein, human
0
Receptor, Serotonin, 5-HT2A
0
Risperidone
L6UH7ZF8HC
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
754-761Subventions
Organisme : Italian Ministry of Health
Pays : International
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Abdolmaleky, H. M., Yaqubi, S., Papageorgis, P., Lambert, A. W., Ozturk, S., Sivaraman, V., & Thiagalingam, S. (2011). Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophrenia Research, 129(2-3), 183-190.
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003). Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Archives of General Psychiatry, 60(12), 1228-1235.
Arranz, M. J., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M., … Murray, R. M. (2000). Pharmacogenetic prediction of clozapine response. The Lancet, 355(9215), 1615-1616.
Arranz, M. J., Munro, J., Sham, P., Kirov, G., Murray, R. M., Collier, D. A., & Kerwin, R. W. (1998). Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Research, 32(2), 93-99.
Arranz, M. J., Rivera, M., & Munro, J. C. (2011). Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs, 25(11), 933-969.
Baou, M., Boumba, V. A., Petrikis, P., Rallis, G., Vougiouklakis, T., & Mavreas, V. (2016). A review of genetic alterations in the serotonin pathway and their correlation with psychotic diseases and response to atypical antipsychotics. Schizophrenia Research, 170(1), 18-29.
Bora, E. (2019). Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: A meta-analysis. Psychological Medicine, 49(12), 1971-1979.
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., … Wong, D. T. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14(2), 87-96.
Carbon, M., & Correll, C. U. (2014). Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues in Clinical Neuroscience, 16(4), 505-524.
Chen, Y. L., Chen, K. P., Chiu, C. C., & Tai, M. H. (2018). Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. BMC Psychiatry, 18(1), 376.
Crow, T. J. (1985). The two-syndrome concept: Origins and current status. Schizophrenia Bulletin, 11(3), 471-488.
Ellingrod, V. L., Lund, B. C., Miller, D., Fleming, F., Perry, P., Holman, T. L., & Bever-Stille, K. (2003). 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacology Bulletin, 37(2), 109-112.
Emsley, R., Rabinowitz, J., Torreman, M., & RIS-INT-35 Early Psychosis Global Working Group. (2003). The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophrenia Research, 61(1), 47-57.
Fijal, B. A., Stauffer, V. L., Kinon, B. J., Conley, R. R., Hoffmann, V. P., Witte, M. M., … Houston, J. P. (2012). Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. The Journal of Clinical Psychiatry, 73(3), 367-371.
Haddad, P. M., Brain, C., & Scott, J. (2014). Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Related Outcome Measures, 5, 43.
Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kitajima, T., Yoshimura, R., Hashimoto, S., … Iwata, N. (2008). Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics, 9(10), 1437-1443.
Kim, B., Choi, E. Y., Kim, C. Y., Song, K., & Joo, Y. H. (2008). Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Human Psychopharmacology: Clinical and Experimental, 23(1), 61-67.
Kim, S., Zavitsanou, K., Gurguis, G., & Webster, M. J. (2012). Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: Exploration of drug targets through the Stanley Neuropathology Integrative Database. European Neuropsychopharmacology, 22(10), 683-694.
Kinon, B. J., Chen, L., Ascher-Svanum, H., Stauffer, V. L., Kollack-Walker, S., Zhou, W., … Kane, J. M. (2010a). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology, 35(2), 581-590.
Kinon, B. J., Chen, L., Ascher-Svanum, H., Stauffer, V. L., Kollack-Walker, S., Zhou, W., … Naber, D. (2010b). Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophrenia Research, 118(1-3), 176-182.
Kinon, B. J., Chen, L., Stauffer, V. L., Sniadecki, J., Ascher-Svanum, H., Kollack-Walker, S., … Kapur, S. (2010). Early onset of antipsychotic action in schizophrenia: Evaluating the possibility of shorter acute efficacy trials. Journal of Clinical Psychopharmacology, 30(3), 286-289.
Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. British Medical Bulletin, 114(1), 169-179.
Lane, H. Y., Chang, Y. C., Chiu, C. C., Chen, M. L., Hsieh, M. H., & Chang, W. H. (2002). Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. American Journal of Psychiatry, 159(9), 1593-1595.
Lane, H. Y., Lee, C. C., Chang, Y. C., Lu, C. T., Huang, C. H., & Chang, W. H. (2004). Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. International Journal of Neuropsychopharmacology, 7(4), 461-470.
Leucht, S., Busch, R., Hamann, J., Kissling, W., & Kane, J. M. (2005). Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biological Psychiatry, 57(12), 1543-1549.
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., … Geddes, J. R. (2017). Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. American Journal of Psychiatry, 174(10), 927-942.
Lydiard, J., & Nemeroff, C. B. (2019). Biomarker-guided tailored therapy. In Frontiers in psychiatry. Advances in experimental medicine and biology (Vol. 1192, pp. 199-224). Singapore: Springer.
Marder, S. R., Davis, J. M., & Chouinard, G. (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the north American trials. The Journal of Clinical Psychiatry, 58(12), 538-546.
McClay, J. L., Adkins, D. E., Åberg, K., Stroup, S., Perkins, D. O., Vladimirov, V. I., … van den Oord, E. J. (2011). Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry, 16(1), 76-85.
Notaras, M., & van den Buuse, M. (2020). Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Molecular Psychiatry. [Epub ahead of print].
Olajossy-Hilkesberger, L., Godlewska, B., Schosser-Haupt, A., Olajossy, M., Wojcierowski, J., Landowski, J., … Kasper, S. (2011). Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology, 64(4), 202-210.
Parsons, M. J., D'Souza, U. M., Arranz, M. J., Kerwin, R. W., & Makoff, A. J. (2004). The-1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biological Psychiatry, 56(6), 406-410.
Polesskaya, O. O., & Sokolov, B. P. (2002). Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. Journal of Neuroscience Research, 67(6), 812-822.
Pouget, J. G., Shams, T. A., Tiwari, A. K., & Müller, D. J. (2014). Pharmacogenetics and outcome with antipsychotic drugs. Dialogues in Clinical Neuroscience, 16(4), 555.
Sacchetti, E., Magri, C., Minelli, A., Valsecchi, P., Traversa, M., Calza, S., … Gennarelli, M. (2017). The GRM7 gene, early response to risperidone, and schizophrenia: A genome-wide association study and a confirmatory pharmacogenetic analysis. The Pharmacogenomics Journal, 17(2), 146-154.
Samara, M. T., Leucht, C., Leeflang, M. M., Anghelescu, I. G., Chung, Y. C., Crespo-Facorro, B., … Kayo, M. (2015). Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. American Journal of Psychiatry, 172(7), 617-629.
Schotte, A., Janssen, P. F. M., Gommeren, W. H. M. L., Luyten, W. H. M. L., van Gompel, P., Lesage, A. S., … Leysen, J. E. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology, 124(1-2), 57-73.
Shi, Y., Li, M., Song, C., Xu, Q., Huo, R., Shen, L., … He, L. (2017). Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. Translational Psychiatry, 7(7), e1170-e1170.
Stern, S., Linker, S., Vadodaria, K. C., Marchetto, M. C., & Gage, F. H. (2018). Prediction of response to drug therapy in psychiatric disorders. Open Biology, 8(5), 180031.
Suliman, S., Hemmings, S. M., & Seedat, S. (2013). Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: Systematic review and meta-regression analysis. Frontiers in Integrative Neuroscience, 7, 55.
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010). Schizophrenia, “just the facts” 5. Treatment and prevention past, present, and future. Schizophrenia Research, 122(1-3), 1-23.
Thomas, P., Srivastava, V., Singh, A., Mathur, P., Nimgaonkar, V. L., Lerer, B., … Deshpande, S. N. (2008). Correlates of response to olanzapine in a north Indian schizophrenia sample. Psychiatry Research, 161(3), 275-283.
Turecki, G., Brière, R., Dewar, K., Antonetti, T., Lesage, A. D., Séguin, M., … Benkelfat, C. (1999). Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. American Journal of Psychiatry, 156(9), 1456-1458.
van den Oord, E. J., Rujescu, D., Robles, J. R., Giegling, I., Birrell, C., Bukszár, J., … Muglia, P. (2006). Factor structure and external validity of the PANSS revisited. Schizophrenia Research, 82(2-3), 213-223.
Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., & Docherty, J. P. (2017). Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Preference and Adherence, 11, 449-468.
Vita, A., Minelli, A., Barlati, S., Deste, G., Giacopuzzi, E., Valsecchi, P., … Gennarelli, M. (2019). Treatment-resistant schizophrenia: Genetic and neuroimaging correlates. Frontiers in Pharmacology, 10, 402.
Voineskos, A. N., Jacobs, G. R., & Ameis, S. H. (2019). Neuroimaging heterogeneity in psychosis: Neurobiological underpinnings and opportunities for prognostic and therapeutic innovation. Biological Psychiatry. [Epub ahead of print].
Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. (2012). Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Research, 137(1-3), 246-250.
Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., … Klein, T. E. (2012). Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 92(4), 414-417.
Yamanouchi, Y., Iwata, N., Suzuki, T., Kitajima, T., Ikeda, M., & Ozaki, N. (2003). Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The Pharmacogenomics Journal, 3(6), 356-361.
Zhang, J. P., & Malhotra, A. K. (2011). Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opinion on Drug Metabolism & Toxicology, 7(1), 9-37.
Zhang, J. P., & Malhotra, A. K. (2018). Recent progress in pharmacogenomics of antipsychotic drug response. Current Psychiatry Reports, 20(4), 24.
Zhu, Y., Li, C., Huhn, M., Rothe, P., Krause, M., Bighelli, I., … Leucht, S. (2017). How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. European Neuropsychopharmacology, 27(9), 835-844.